Ads
related to: hematology
Search results
Data Breach at South Texas Oncology and Hematology Leaks SSNs of Over 170k Patients | JD Supra
JD Supra· 2 days agoOn June 17, 2024, South Texas Oncology and Hematology (“STOH”) filed a notice of data breach with the Attorney General of Texas after wrapping up an investigation into a February ...
EHA 2024: Monoclonal antibodies continue to dominate multiple myeloma treatments
Pharmaceutical Technology via Yahoo Finance· 14 hours agoMany significant Phase I-III studies targeting haematological malignancies, such as multiple myeloma...
EIRMC employee retiring after 55 year career
Idaho State Journal· 5 days agoKeila Poulsen, hematology and histology supervisor, is retiring after 55 years of service to Eastern Idaho Regional Medical Center. Keila is considered...
Another Study Finds CRISPR Gene Therapy Fights Sickle Cell | Fox 11 Tri Cities Fox 41 Yakima
FOX 11/41 Yakima· 4 days ago“It’s encouraging that this gene-editing treatment continues to show promising efficacy for sickle...
EHA 2024: AstraZeneca’s Calquence plus chemoimmunotherapy offers new standard for MCL
Pharmaceutical Technology via Yahoo Finance· 5 days agoOn 16 June, 2024, during the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid,...
EHA 2024: Brukinsa/Venclexta for CLL/SLL lacks control arm in SEQUOIA trial
Clinical Trials Arena via Yahoo Finance· 5 days agoAt the 2024 Congress of the European Hematology Association (EHA 2024) on 14 June, preliminary...
Mesoblast (NASDAQ:MESO) Shares Gap Up to $7.24
ETF DAILY NEWS· 2 days agoShares of Mesoblast Limited (NASDAQ:MESO – Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $7.24, but opened at $7.39. Mesoblast shares last ...
Gene editing technology is revolutionizing disease treatment | The Excerpt
USA TODAY via Yahoo News· 2 days agoShengdar Q. Tsai, associate member and principal investigator of the Department of Hematology at St. Jude Children’s Research Hospital, joins The Excerpt to talk about how ...
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology - HUTCHMED...
Benzinga· 5 days ago— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of prior lines of
Regeneron touts success with bispecific antibody in multiple myeloma trial
Clinical Trials Arena via Yahoo Finance· 5 days agoRegeneron has released encouraging trial results for its multiple myeloma antibody, linvoseltamab....
Ads
related to: hematology
